Abstract：
UNASSIGNED: Agitation is a common prehospital problem and frequently presents without a clear etiology. Given the dynamic environment of the prehospital setting, there has historically been a varied approach to treating agitation with a heavy reliance on parenteral medications. Newer best practice guidelines recommend the incorporation of oral medications to treat patients experiencing agitation. Therefore, we evaluated the use of oral risperidone in a single system after a change in protocol occurred.
UNASSIGNED: This was conducted as a retrospective chart review of an urban/suburban Emergency Medical Services system over the period of 8 months. The first day this medication was implemented throughout the service was included. Charts were included for selection if they included risperidone oral dissolving tablet (ODT) as a charted medication. The primary outcome was administration of additional medications to treat agitation. Exploratory outcome measures included acceptance of medication, documented injury to paramedics, documented injuries to patients, scene times, and adverse events that could possibly be linked to the medication.
UNASSIGNED: A total of 552 records were screened for inclusion. Risperidone was offered to 530 patients and accepted by 512 (96.6%). Of these 512 patients, the median age of included patients was 39 years old (IQR 29-52 years old) with a range of 18-89 years old. Rescue or additional medications for agitation were required in 9 (1.8%) cases. There were a total of 4 (0.8%) potential complications following administration of risperidone. There were no reported assaults with subsequent injuries to prehospital personnel or injuries sustained by patients reported in this study.
UNASSIGNED: Risperidone ODT was found to be a safe and effective medication to treat mild agitation in a large urban and suburban EMS system. The need for additional medications to treat agitation was rare, and there were no documented injuries to either patients or paramedics.
UNASSIGNED: This was conducted as a retrospective chart review of an urban/suburban Emergency Medical Services system over the period of 8 months. The first day this medication was implemented throughout the service was included. Charts were included for selection if they included risperidone oral dissolving tablet (ODT) as a charted medication. The primary outcome was administration of additional medications to treat agitation. Exploratory outcome measures included acceptance of medication, documented injury to paramedics, documented injuries to patients, scene times, and adverse events that could possibly be linked to the medication.
UNASSIGNED: A total of 552 records were screened for inclusion. Risperidone was offered to 530 patients and accepted by 512 (96.6%). Of these 512 patients, the median age of included patients was 39 years old (IQR 29-52 years old) with a range of 18-89 years old. Rescue or additional medications for agitation were required in 9 (1.8%) cases. There were a total of 4 (0.8%) potential complications following administration of risperidone. There were no reported assaults with subsequent injuries to prehospital personnel or injuries sustained by patients reported in this study.
UNASSIGNED: Risperidone ODT was found to be a safe and effective medication to treat mild agitation in a large urban and suburban EMS system. The need for additional medications to treat agitation was rare, and there were no documented injuries to either patients or paramedics.
摘要：
目的：躁动是一种常见的院前问题，并且经常在没有明确病因的情况下出现。鉴于院前设置的动态环境，从历史上看，严重依赖肠胃外药物治疗躁动的方法多种多样。较新的最佳实践指南建议使用口服药物来治疗躁动患者。因此,我们评估了方案发生变化后,在单一系统中口服利培酮的使用情况.方法：这是针对8个月内的城市/郊区急诊医疗服务系统进行的回顾性图表审查。包括在整个服务中实施该药物的第一天。如果它们包括利培酮口服溶解片剂(ODT)作为图表药物,则包括用于选择的图表。主要结果是给予其他药物治疗躁动。探索性结果测量包括接受药物，有记录的护理人员受伤,记录患者受伤情况,场景时间,以及可能与药物有关的不良事件。结果：共筛选552条记录纳入。利培酮被提供给530名患者，并被512名（96.6％）接受。在这512名患者中，纳入患者的中位年龄为39岁(IQR29~52岁),范围为18~89岁.9例（1.8％）需要抢救或额外的躁动药物。服用利培酮后，共有4例（0.8％）潜在并发症。本研究中没有报告院前人员随后受伤或患者受伤的袭击。结论：在大型城市和郊区EMS系统中，发现利培酮ODT是治疗轻度躁动的安全有效药物。很少需要额外的药物来治疗躁动，并且没有记录到患者或护理人员受伤。
